United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Friday, July 31st. The shares were sold at an average price of $518.96, for a total value of $4,930,120.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at $168,372,939.28. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
United Therapeutics Stock Performance
Shares of United Therapeutics stock opened at $516.31 on Tuesday. The company has a 50-day simple moving average of $542.59 and a two-hundred day simple moving average of $533.07. United Therapeutics Corporation has a one year low of $287.64 and a one year high of $609.35. The company has a market capitalization of $21.92 billion, a PE ratio of 19.06, a P/E/G ratio of 1.73 and a beta of 0.59.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company's revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the firm earned $6.63 EPS. On average, equities analysts predict that United Therapeutics Corporation will post 26.65 earnings per share for the current fiscal year.
Institutional Trading of United Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. Handelsbanken Fonder AB boosted its holdings in shares of United Therapeutics by 4.1% in the 2nd quarter. Handelsbanken Fonder AB now owns 13,120 shares of the biotechnology company's stock valued at $7,109,000 after acquiring an additional 520 shares during the last quarter. PensionDanmark Pensionsforsikringsaktieselskab raised its holdings in shares of United Therapeutics by 7.4% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 11,058 shares of the biotechnology company's stock worth $5,992,000 after purchasing an additional 760 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of United Therapeutics by 79.2% during the second quarter. Assenagon Asset Management S.A. now owns 84,538 shares of the biotechnology company's stock worth $45,805,000 after purchasing an additional 37,355 shares during the last quarter. GAMMA Investing LLC lifted its position in United Therapeutics by 10.3% during the second quarter. GAMMA Investing LLC now owns 1,769 shares of the biotechnology company's stock valued at $958,000 after purchasing an additional 165 shares during the period. Finally, Versant Capital Management Inc lifted its position in United Therapeutics by 93.6% during the second quarter. Versant Capital Management Inc now owns 182 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 88 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities analysts recently commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research note on Thursday, May 7th. TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Raymond James Financial began coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price target for the company. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $648.33.
Read Our Latest Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
